Sorafenib Following Stem Cell Transplantation Feasible in Pediatric Acute Myeloid Leukemia
the Cancer Therapy Advisor take:
According to a new study published in the journal Pediatric Blood and Cancer, researchers at Fred Hutchinson Cancer Research Center and Seattle Children's Hospital in Seattle, Washington, have found that sorafenib treatment is feasible and well-tolerated in pediatric patients with FLT3/ITD+ acute myeloid leukemia (AML) following allogenic stem cell transplantation (HSCT).
For the retrospective study, researchers identified 15 pediatric patients with FLT3/ITD+ AML treated with sorafenib within 18 months of receiving HSCT. These patients either received sorafenib as prophylaxis because they were at very high risk for relapse or at the time of recurrence. Results showed that 73% of patients experienced significant toxicities.
Of those, researchers found that 55% had received sorafenib at doses above the maximum tolerated dose of sorafenib for pediatric leukemia.
Of note, sorafenib was not found to exacerbate graft versus host disease. In addition, all patients who received sorafenib for minimal residual disease immediately before receiving a transplant or with emergence post-HSCT are alive and continue to be in remission at a median of 48 months after transplant.
The findings suggest that sorafenib is feasible and well-tolerated in pediatric patients with FLT3/ITD+ AML, particularly those with minimal residual disease, but prospective controlled studies are warranted to determine the most appropriate sorafenib dose in these patients.
Sorafenib treatment is feasible and well-tolerated in pediatric patients with FLT3/ITD+ AML.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Larotrectinib Continues to Show Efficacy in TRK-Fusion Cancers
- First-Line Nivolumab Alone or With Ipilimumab Continues to Show Durable Survival Benefits in Advanced Melanoma
- Talazoparib Improves PROs in BRCA-Positive Triple-Negative Breast Cancer
- Entrectinib Shrank NTRK Fusion-Positive Solid Tumors
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer